Citations 1
Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Long-term follow-up of patient-reported outcomes (PROs) in the phase III PERSIST-1 trial.
Harrison, Claire , Cervantes, Francisco , Dean, James , Wang, Lixia , Granston, Tanya, Yang, Yoojung, Mesa, Ruben A. , Vannucchi, Alessandro M. , Mead, Adam J.
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7067-7067
